- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Linagliptin applicable across wide group of T2DM patients- Latest Indian Position Paper
Overview
As per the latest Indian position statement released in the Journal of the Association of Physicians of India, August 2023 issue, Linagliptin therapy is simplifying the management of T2DM with efficacy & applicability across a wide range of patients.
Key expert opinions from this Position paper include:
1. 94.3% of Healthcare Professionals (HCPs) opined that a single 5 mg once daily dosing of linagliptin across diverse T2DM patient profiles, irrespective of cardiac, renal, or hepatic comorbidities, eases up management of T2DM
2. Linagliptin is used in both Drug naïve and uncontrolled T2DM patients.
Linagliptin has multiple clinical and safety advantages across a wide group of T2DM patients, making it potentially an evergreen oral anti-diabetic agent and combination of Linagliptin & Dapagliflozin and Evergreen DUO.
Reference:
Mithal, A., et.al. (2023). Simplifying Type 2 DM Care with Linagliptin: A Position Paper. The Journal of the Association of Physicians of India, 71(8), 11–12. https://doi.org/10.59556/japi.71.0324
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)